40741-46-6

Basic information

• Product Name: 6-Chloropyridine-3-sulfonamide
• Synonyms: 6-CHLOROPYRIDINE-3-SULFONAMIDE;3-Pyridinesulfonamide,6-chloro-(7CI,9CI);6-Chloro-pyridine-3-sulfonic acid aMide;6-Chloro-3-pyridinesulfonaMide
• CAS NO: 40741-46-6
• Molecular Formula: C₅H₅ClN₂O₂S
• Molecular Weight: 192.62
• Product Categories: SULFONAMIDE;Pyridines
• Mol File: 40741-46-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 383.2 °C at 760 mmHg
• Flash Point: 185.6 °C
• Appearance: /
• Density: 1.558 g/cm³
• Vapor Pressure: 4.47E-06mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.24±0.60(Predicted)
• CAS DataBase Reference: 6-Chloropyridine-3-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloropyridine-3-sulfonamide(40741-46-6)
• EPA Substance Registry System: 6-Chloropyridine-3-sulfonamide(40741-46-6)

Safety Data

• Hazardous Substances Data: 40741-46-6(Hazardous Substances Data)

Usage

Description

6-Chloropyridine-3-sulfonamide is a heterocyclic compound characterized by the presence of a chlorine atom at the 6th position and a sulfonamide group at the 3rd position of the pyridine ring. It serves as a versatile building block in the field of chemical synthesis and holds potential applications in the pharmaceutical industry.

Uses

Used in Chemical Synthesis:
6-Chloropyridine-3-sulfonamide is used as a heterocyclic building block for the synthesis of various complex organic compounds. Its unique structural features make it a valuable intermediate in the development of novel chemical entities.
Used in Pharmaceutical Industry:
6-Chloropyridine-3-sulfonamide is used as a key intermediate in the synthesis of diuretics and carbonic anhydrase inhibitors. Its incorporation into these therapeutic agents aids in the development of medications that can effectively manage fluid retention and conditions related to the imbalance of acid-base in the body.

InChI:InChI=1/C5H5ClN2O2S/c6-5-2-1-4(3-8-5)11(7,9)10/h1-3H,(H2,7,9,10)

Upstream product

• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 6684-46-4 6-hydroxy-pyridine-3-sulfonic acid 
• 876489-80-4 1-methyl-6-oxo-1,6-dihydro-pyridine-3-sulfonic acid 
• 6684-39-5 2-chloropyridine-5-sulfonyl chloride 

Downstream Products

• 1057677-68-5 6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]pyridine-3-sulfonic acid amide 
• 1083334-54-6 6-(2,6-dimethoxy-phenyl)-pyridine-3-sulfonic acid 2,4-dichloro-benzoylamide 
• 928141-28-0 6-chloro-N-{3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl}pyridine-3-sulfonamide 
• 1021895-26-0 6-chloro-pyridine-3-sulfonic acid 2,4-dichlorobenzoylamide 
• 38029-90-2 2-(4-Methyl-1-piperazinyl)-pyridin-5-sulfonamid 
• 96591-89-8 6-(1-Methyl-1H-imidazol-2-ylsulfanyl)-pyridine-3-sulfonic acid amide 
• 89322-91-8 6-hydroxy-pyridine-3-sulfonic acid amide 
• 57187-73-2 6-aminopyridine-3-sulfonamide 
• 88614-57-7 6-benzylamino-pyridine-3-sulfonic acid amide 
• 856955-32-3 6-methoxypyridine-3-sulfonamide 

Relevant articles and documents

Process for Preparation of Sulfonyl Carbamate Bile Acid Derivatives

The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II): or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR or TGRS modulators. Specifically, the present invention relates to bile acid derivatives and methods for their preparation and use. The present invention relates to a process for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),

MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS

A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.

Discovery of novel HCV inhibitors: Synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B

A novel series of 6-(indol-2-yl)pyridine-3-sulfonamides was prepared and evaluated for their ability to inhibit HCV RNA replication in the HCV replicon cell culture assay. Preliminary optimization of this series furnished compounds with low nanomolar potency against the HCV genotype 1b replicon. Among these, compound 8c has identified as a potent HCV replicon inhibitor (EC50 = 4 nM) with a selectivity index with respect to cellular GAPDH of more than 2500. Further, compound 8c had a good pharmacokinetic profile in rats with an IV half-life of 6 h and oral bioavailability (F) of 62%. Selection of HCV replicon resistance identified an amino acid substitution in HCV NS4B that confers resistance to these compounds. These compounds hold promise as a new chemotype with anti-HCV activity mediated through an underexploited viral target.